RPRX (Royalty Pharma) Receipts from Customers

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

RPRX Royalty Pharma PLC RPRX
73 GF Score
Price $58.61
GF Value $33.47
Valuation Significantly Overvalued
! 9 Warning Signs
View Full Analysis

What is Royalty Pharma Receipts from Customers?

Receipts from Customers only applicable to companies reporting Cash Flow from Operations in direct method.

RPRX
73GF Score
Royalty Pharma PLC RPRX
Receipts from Customers is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Royalty Pharma (RPRX) Overvalued in 2026?

Based on GuruFocus' analysis, Royalty Pharma stock appears to be overvalued. The current stock price of $58.61 is trading 75.1% above its estimated GF Value™ of $33.47. GuruFocus considers Royalty Pharma to be Significantly Overvalued.

Key valuation signals for RPRX:

  • Receipts from Customers:
  • GF Value™: $33.47 vs. price of $58.61 (75.1% above fair value)
  • GF Score™: 73/100 with 9 warning signs

No single metric tells the full story. See the RPRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Royalty Pharma Business Description

Other Exchanges RPD:Germany
Address 110 East 59th Street, New York, NY, USA, 10022
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
73GF Score

Get the complete analysis for RPRX

Receipts from Customers is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$58.61
Price
$33.47
GF Value